Rapid-Myco Technologies

About Rapid-Myco Technologies

Rapid Myco Technologies is at the forefront of developing a transformative diagnostic platform aimed at the swift detection of mycobacterial infections in both commercial livestock and humans. The company addresses the growing need for effective diagnostic solutions, particularly in the context of Bovine Tuberculosis (bTB) caused by M. bovis, a zoonotic disease that poses significant health risks. Rapid Myco's innovative approach leverages a novel, rapid 8-hour bacteriophage-based qPCR test, which is the only phage-based qPCR test capable of working with diverse sample types including milk, blood, fecal, and potentially sputum samples. This patent-pending technology offers a significant advancement over traditional methods, providing faster and more reliable results. The primary market for Rapid Myco's solutions includes dairy and beef industries, where the need for efficient and accurate testing is critical. By offering a cutting-edge diagnostic tool, Rapid Myco not only enhances disease management but also contributes to the broader efforts in controlling zoonotic diseases globally. The business model likely involves selling these diagnostic tests to veterinary clinics, livestock producers, and potentially healthcare providers, generating revenue through the sale of test kits and related services.